Press Releases

The Parenteral Drug Association (PDA) announces senior regulatory experts to speak during opening session of the 2022 PDA Annual Meeting, the first full in-person signature event held by PDA since 2019. The PDA Annual Meeting takes place at the Hyatt Regency in Dallas, Tx., April 4-6.

The Parenteral Drug Association (PDA) today announced the availability of ANSI/PDA Standard 02-2021 Cryopreservation of Cells for Use in Cell Therapies, Gene Therapies, and Regenerative Medicine Manufacturing: An Introduction and Best Practices Approach on How to Prepare, Cryopreserve, and Recover Cells, Cell Lines, and Cell-Based Tissue Products.

The Parenteral Drug Association (PDA) today announced the results of the 2021 Board of Directors Election for the term beginning January 1, 2022.

The Parenteral Drug Association (PDA) today announced the winners of the 2021 PDA Drug Delivery Innovation Awards during the opening plenary session of the 2021 PDA Universe of Pre-Filled Syringes and Injection Devices.

The Parenteral Drug Association (PDA) today announced the availability of its newest membership type, the Early Career Professional.

The Parenteral Drug Association (PDA) today announced the availability of industry standard, ANSI/PDA Standard 05-2021 Consensus Method for Rating Filters for Mycoplasma, available now for purchase in the PDA Bookstore.

The Parenteral Drug Association, Inc. (PDA) has announced that Glenn Wright, Vice President of Scientific and Regulatory Affairs, was named the Chairman of the Product Quality Research Institute’s (PQRI) Board of Directors. Mr. Wright has participated in PQRI since 2003.

The Parenteral Drug Association (PDA) announced the beginning of its 75th Anniversary celebration. The 2021 PDA Annual Meeting (15–17 March) and the Honor Awards Ceremony (24 March), both virtual online events, served as the official launch of the diamond anniversary.

The Parenteral Drug Association (PDA) announced the availability of ANSI/PDA Standard 04-2021 Phage Retention Nomenclature Rating for Small and Large Virus-Retentive Filters.

Bethesda, Md. – The Parenteral Drug Association (PDA) today announced it has signed an agreement to collaborate with Deloitte Consulting, LLP and the U.S. FDA’s Compounding Quality Center of Excellence to provide training to large pharmaceutical compounders in a variety of Good Manufacturing Practices (GMP)-related functions critical to improving the overall quality of compound drugs.

Enables Access to Healthcare Coverage for their members with Immediate Savings and Simple Enrollment

Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the results of the 2020 Board of Directors Election for the term beginning January 1, 2021.

Bethesda, Md., – The Parenteral Drug Association (PDA) announced the winners of the 2020 PDA Drug Delivery Innovation Awards at the 2020 PDA Universe of Pre-Filled Syringes and Injection Devices, Oct. 5-8, a virtual event. Awardees were recognized for their technical innovations in advancing the field of bio/pharmaceutical delivery devices.

Bethesda, Md., – The Parenteral Drug Association (PDA) and BioPhorum today announced that the Sterile Filtration Quality Risk Management (SFQRM), jointly created by the two organizations, has completed its final publication to help clarify industry thinking on the implications of pre-use post-sterilization integrity testing (PUPSIT) of sterilizing filters. The work product includes two research papers and two points-to-consider technical documents.

Bethesda, Md. – The Parenteral Drug Association (PDA) today announced that it has confirmed Douglas Throckmorton, MD, Deputy Director for Regulatory Programs, Center for Drug Evaluation and Research (CDER), U.S. FDA, as an opening plenary speaker of the 2020 PDA/FDA Joint Regulatory Conference, which will be held virtually Sept. 14 – 16.

Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the availability of BSR/PDA Standard 02-201x, Cryopreservation of Cells for Use in Cell Therapies and Regenerative Medicine Manufacturing for public comment. To receive a copy of this draft standard, email PDA at [email protected] The public comments period concludes September 7, 2020 EDT. There is no charge for the draft standard.

Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the availability of a new website for the PDA Foundation, a 501(c)(3) nonprofit founded in 1997 to help support PDA and other industry activities. This new website makes it easier for industry stakeholders to donate money for various activities, as it includes an online processing system.

Bethesda, Md. – The Parenteral Drug Association, Inc. (PDA) today announced two new volunteer opportunities and changes to its Board of Directors/Executive Committee following its spring Board of Directors meeting.

Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the availability of ANSI/PDA Standard 001-2020, Enhanced Purchasing Controls to Support the Bio-Pharmaceutical, Pharmaceutical, Medical Devices, and Combination Products Industries, which was approved by the ANSI Board of Standards Review on March 13, 2020.

Bethesda, Md. – The Parenteral Drug Association, Inc. (PDA) today announced the availability of its 2020 – 2026 Strategic Plan, which was developed to assist PDA in achieving its vision to be the premier global leader in advancing bio/pharmaceutical manufacturing, science, technology, and regulation to enable members to better serve patients. The plan was developed by PDA’s Strategic Planning Committee at the direction of the PDA Board of Directors.